Relay Therapeutics, Inc. leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety & efficacy. Learn more ...

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

New research reveals how tiny electrical gates in the brain, known as NMDA receptors, control learning, memory, and neuron survival.

Artificial intelligence (AI) is fundamentally reshaping the landscape of solid tumor (ST) drug development. By integrating multi-omics data, spatial ...

Subject to the terms of the Rights Plan, the rights will expire on October 27, 2026, unless the rights are earlier redeemed or exchanged by Neuphoria. Additional information regarding the Rights Plan ...

Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced the appointment of Timothy Noyes as President and ...

The National Academy of Medicine (NAM) has elected Mohammed K. Ali, MD, MSc, Stephen F. Traynelis, PhD, Wanda Barfield, MD, MPH, and Ravi Thadhani ...

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fisca ...

Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced preliminary clinical and preclinical ...

Sudo Biosciences, ("Sudo"), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced positive topline results from ...